Jing An
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Jing An has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Chuanlan Ju
Department of Public Health, Yantai Municipal Hospital of Traditional Chinese Medicine, Shandong, China
2 shared publications - Huiyi Sun
Department of Spleen and Stomach Diseases, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, China
2 shared publications - Jian-Ping Liu
Centre for Evidence-based Chinese Medicine, Beijing University of Chinese Medicine, China
2 shared publications - Liming Hu
Department of Spleen, Stomach, Liver & Gallbladder Diseases, Dongfang Hospital, Beijing University of Chinese Medicine, Beijing, China
2 shared publications - Yuan Sun
School of Traditional Chinese Medicine, Centre for Evidence-Based Chinese Medicine, Beijing University of Chinese Medicine, 11 Beisanhuan East Road, Chaoyang District, Beijing, 100029, China, 86 17800176627
2 shared publications - Zeyang Shi
School of Traditional Chinese Medicine, Centre for Evidence-Based Chinese Medicine, Beijing University of Chinese Medicine, 11 Beisanhuan East Road, Chaoyang District, Beijing, 100029, China, 86 17800176627
2 shared publications
Latest Publications
- Open Access
- 22 December 2025
- Published by JMIR Publications Inc. in Journal of Medical Internet Research
- Vol. 27, e71944
Prognostic Prediction Models for Ulcerative Colitis: Systematic Review and Meta-Analysis
Background: Ulcerative colitis (UC) is a chronic inflammatory disease with highly variable symptoms and severity. Prognostic models for UC support precision medicine by enabling personalized treatment strategies. However, the quality and clinical utility of these models remain inadequately assessed. Objective: This study aimed to systematically review and critically evaluate the development, performance, and applicability of prognostic prediction models for UC. Methods: To identify prognostic models for UC, a comprehensive search was conducted in PubMed, Embase, the Cochrane Library, Web of Science, SinoMed, China National Knowledge Infrastructure, Wanfang, and VIP Database up to November 2, 2024. Extracted data included study characteristics, model development methods, validation metrics (eg, area under the curve and concordance index). The risk of bias and applicability were evaluated using the Prediction Model Risk of Bias Assessment Tool. A meta-analysis was conducted to assess model performance. Results: A total of 30 studies involving 7452 patients with UC were included, with the largest numbers conducted in China (11/30, 37%) and Japan (4/30, 13%). Most studies were retrospective (22/30, 73%). The primary objectives of the UC prognostic models included predicting therapeutic effects and responses to treatment, particularly to tumor necrosis factor-alpha inhibitors (eg, infliximab and adalimumab), and assessing the risks of surgery, disease progression, or relapse. Logistic regression was the most frequently used method for both predictor selection (6/30, 20%) and model construction (12/30, 40%). Common predictors included age, C-reactive protein, albumin, hemoglobin, disease extent, and Mayo scores. The meta-analysis yielded a pooled area under the curve of 0.84 (95% CI 0.77‐0.92). Most studies exhibited a high risk of bias (29/30, 97%), particularly in participant selection and statistical analysis. Applicability concerns were identified in 18 studies (18/30, 60%), primarily due to subgroup-specific designs that limited the generalizability of the findings. External validation data (14/30, 47%) were limited, and only a small number of studies (12/30, 40%) included calibration curves or decision curve analysis. Conclusions: This study demonstrates that prognostic models for UC have some potential in predictive performance and clinical application. However, most models are constrained by high bias risk, insufficient external validation, and limited generalizability due to small sample sizes and subgroup-specific designs. Future research should prioritize multicenter validations, refine model development approaches, and enhance model applicability to support broader clinical implementation.
- 22 December 2025
- Published by JMIR Publications Inc. in Journal of Medical Internet Research
- Vol. 27, e71944
Open AccessPrognostic Prediction Models for Ulcerative Colitis: Systematic Review and Meta-Analysis
Background: Ulcerative colitis (UC) is a chronic inflammatory disease with highly variable symptoms and severity. Prognostic models for UC support precision medicine by enabling personalized treatment strategies. However, the quality and clinical utility of these models remain inadequately assessed. Objective: This study aimed to systematically review and critically evaluate the development, performance, and applicability of prognostic prediction models for UC. Methods: To identify prognostic models for UC, a comprehensive search was conducted in PubMed, Embase, the Cochrane Library, Web of Science, SinoMed, China National Knowledge Infrastructure, Wanfang, and VIP Database up to November 2, 2024. Extracted data included study characteristics, model development methods, validation metrics (eg, area under the curve and concordance index). The risk of bias and applicability were evaluated using the Prediction Model Risk of Bias Assessment Tool. A meta-analysis was conducted to assess model performance. Results: A total of 30 studies involving 7452 patients with UC were included, with the largest numbers conducted in China (11/30, 37%) and Japan (4/30, 13%). Most studies were retrospective (22/30, 73%). The primary objectives of the UC prognostic models included predicting therapeutic effects and responses to treatment, particularly to tumor necrosis factor-alpha inhibitors (eg, infliximab and adalimumab), and assessing the risks of surgery, disease progression, or relapse. Logistic regression was the most frequently used method for both predictor selection (6/30, 20%) and model construction (12/30, 40%). Common predictors included age, C-reactive protein, albumin, hemoglobin, disease extent, and Mayo scores. The meta-analysis yielded a pooled area under the curve of 0.84 (95% CI 0.77‐0.92). Most studies exhibited a high risk of bias (29/30, 97%), particularly in participant selection and statistical analysis. Applicability concerns were identified in 18 studies (18/30, 60%), primarily due to subgroup-specific designs that limited the generalizability of the findings. External validation data (14/30, 47%) were limited, and only a small number of studies (12/30, 40%) included calibration curves or decision curve analysis. Conclusions: This study demonstrates that prognostic models for UC have some potential in predictive performance and clinical application. However, most models are constrained by high bias risk, insufficient external validation, and limited generalizability due to small sample sizes and subgroup-specific designs. Future research should prioritize multicenter validations, refine model development approaches, and enhance model applicability to support broader clinical implementation.
- Open Access
- 28 November 2025
- Published by JMIR Publications Inc. in JMIR Medical Informatics
- Vol. 13, e78644
Predictive Performance of Radiomics-Based Machine Learning for Colorectal Cancer Recurrence Risk: Systematic Review and Meta-Analysis
Background: Predicting colorectal cancer (CRC) recurrence risk remains a challenge in clinical practice. Owing to the widespread use of radiomics in CRC diagnosis and treatment, some researchers recently explored the effectiveness of radiomics-based models in forecasting CRC recurrence risk. Nonetheless, the lack of systematic evidence of the efficacy of such models has hampered their clinical adoption. Objective: This study aimed to explore the value of radiomics in predicting CRC recurrence, providing a scholarly rationale for developing more specific interventions. Methods: Overall, 4 databases (Embase, PubMed, the Cochrane Library, and Web of Science) were searched for relevant articles from inception to January 1, 2025. We included studies that developed or validated radiomics-based machine learning models for predicting CRC recurrence using computed tomography or magnetic resonance imaging and provided discriminative performance metrics (c-index). Nonoriginal articles, studies that did not develop a model, and those lacking clear outcome measures were excluded from the study. The quality of the included original studies was assessed using the Radiomics Quality Score. A bivariate mixed-effects model was used to conduct a meta-analysis in which the c-index values with 95% CI were pooled. For the meta-analysis, subgroup analyses were conducted separately on the validation and training sets. Results: This meta-analysis included 17 original studies involving 4600 patients with CRC. The quality of the identified studies was low (mean Radiomics Quality Score 13.23/36, SD 2.56), with limitations in prospective design and biological validation. In the validation set, the c-index values based on clinical features, radiomics features, and radiomics features combined with clinical features were 0.73 (95% CI 0.68‐0.79), 0.80 (95% CI 0.75‐0.85), and 0.83 (95% CI 0.79‐0.87), respectively. In the internal validation set, the c-index values based on clinical features, radiomics features, and radiomics features+clinical features were 0.70 (95% CI 0.61‐0.79), 0.83 (95% CI 0.78‐0.88), and 0.83 (95% CI 0.78‐0.88), respectively. Finally, in the external validation set, the c-index values based on clinical features, radiomics features, and radiomics features combined with clinical features were 0.76 (95% CI 0.70‐0.83), 0.75 (95% CI 0.66‐0.83), and 0.83 (95% CI 0.78‐0.88), respectively. Conclusions: Radiomics-based machine learning models, especially those integrating radiomics and clinical features, showed promising predictive performance for CRC recurrence risk. However, this study has several limitations, such as moderate study quality, limited sample size, and high heterogeneity in modeling approaches. These findings suggest the potential clinical value of integrated models in risk stratification and their potential to enhance personalized treatment, though further high-quality prospective studies are warranted.
- 28 November 2025
- Published by JMIR Publications Inc. in JMIR Medical Informatics
- Vol. 13, e78644
Open AccessPredictive Performance of Radiomics-Based Machine Learning for Colorectal Cancer Recurrence Risk: Systematic Review and Meta-Analysis
Background: Predicting colorectal cancer (CRC) recurrence risk remains a challenge in clinical practice. Owing to the widespread use of radiomics in CRC diagnosis and treatment, some researchers recently explored the effectiveness of radiomics-based models in forecasting CRC recurrence risk. Nonetheless, the lack of systematic evidence of the efficacy of such models has hampered their clinical adoption. Objective: This study aimed to explore the value of radiomics in predicting CRC recurrence, providing a scholarly rationale for developing more specific interventions. Methods: Overall, 4 databases (Embase, PubMed, the Cochrane Library, and Web of Science) were searched for relevant articles from inception to January 1, 2025. We included studies that developed or validated radiomics-based machine learning models for predicting CRC recurrence using computed tomography or magnetic resonance imaging and provided discriminative performance metrics (c-index). Nonoriginal articles, studies that did not develop a model, and those lacking clear outcome measures were excluded from the study. The quality of the included original studies was assessed using the Radiomics Quality Score. A bivariate mixed-effects model was used to conduct a meta-analysis in which the c-index values with 95% CI were pooled. For the meta-analysis, subgroup analyses were conducted separately on the validation and training sets. Results: This meta-analysis included 17 original studies involving 4600 patients with CRC. The quality of the identified studies was low (mean Radiomics Quality Score 13.23/36, SD 2.56), with limitations in prospective design and biological validation. In the validation set, the c-index values based on clinical features, radiomics features, and radiomics features combined with clinical features were 0.73 (95% CI 0.68‐0.79), 0.80 (95% CI 0.75‐0.85), and 0.83 (95% CI 0.79‐0.87), respectively. In the internal validation set, the c-index values based on clinical features, radiomics features, and radiomics features+clinical features were 0.70 (95% CI 0.61‐0.79), 0.83 (95% CI 0.78‐0.88), and 0.83 (95% CI 0.78‐0.88), respectively. Finally, in the external validation set, the c-index values based on clinical features, radiomics features, and radiomics features combined with clinical features were 0.76 (95% CI 0.70‐0.83), 0.75 (95% CI 0.66‐0.83), and 0.83 (95% CI 0.78‐0.88), respectively. Conclusions: Radiomics-based machine learning models, especially those integrating radiomics and clinical features, showed promising predictive performance for CRC recurrence risk. However, this study has several limitations, such as moderate study quality, limited sample size, and high heterogeneity in modeling approaches. These findings suggest the potential clinical value of integrated models in risk stratification and their potential to enhance personalized treatment, though further high-quality prospective studies are warranted.